(Q35903762)

11 August 2017

Use of fibrates in the United States and Canada (English)

1 reference

11 August 2017

0 references

4

Dennis T Ko

1 reference

11 August 2017

6

Harlan M Krumholz

1 reference

11 August 2017

Jack V Tu

2

0 references

Joseph S. Ross

object named as

Joseph S Ross

series ordinal

3

0 references

Cynthia A Jackevicius

series ordinal

1

object named as

Cynthia A Jackevicius

1 reference

11 August 2017

Daniel Carreon

5

1 reference

PMC publication ID

3332101

11 August 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

The Journal of the American Medical Association

11 August 2017

1 reference

11 August 2017

305

1 reference

11 August 2017

12

1 reference

11 August 2017

1217-1224

1 reference

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332101

Effects of combination lipid therapy in type 2 diabetes mellitus

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332101

Medicine's ethical responsibility for health care reform--the Top Five list

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332101

Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332101

Long-term trends in use of and expenditures for cardiovascular medications in Canada

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332101

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332101

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332101

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332101

Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332101

FDA adverse event reports on statin-associated rhabdomyolysis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332101

Cerivastatin and reports of fatal rhabdomyolysis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332101

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332101

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332101

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332101

Use of ezetimibe in the United States and Canada

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332101

International prices and availability of pharmaceuticals in 2005.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332101

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332101

Risk of adverse events with fibrates

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332101

Plasma concentrations of active simvastatin acid are increased by gemfibrozil

24 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21427374

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

1 reference

https://pubmed.ncbi.nlm.nih.gov/21427374

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1001/JAMA.2011.353

1 reference

11 August 2017

1 reference

PMC publication ID

3332101

11 August 2017

PubMed publication ID

21427374

1 reference

PMC publication ID

3332101